A Phase 4 interventional study of paliperidone palmitate and oral risperidone in Schizophrenia, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Terminated at 76 sites in 12 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2012-09-10.
Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 60th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 47th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ortho-McNeil Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Ortho-McNeil Janssen Scientific Affairs, LLC is the lead sponsor of 16 studies on the registry; none are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 89th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2009, is one of 47 in phase 4, and was the 122nd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
This is a Prospective, Randomized, Active-controlled, Rater-blinded Study to to assess the efficacy of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse. Recently diagnosed is defined as first diagnosis of any psychotic disorder within 5 years prior to screening. High risk of relapse is defined as having documented occurrence of 3 periods of breakthrough symptoms that required a change in patient care per the investigator's judgment (e.g., increase in dose, addition of a new drug, increase in the level of psychiatric care, notable increases in the frequency or intensity of patient contact required to maintain outpatient status, psychiatric hospitalization, etc.) within the previous 24 months, including 1 such period within the previous 6 months. Safety evaluations will include Adverse Event (AE) reporting, hematology and clinical chemistry laboratory tests, vital signs, electrocardiogram (ECG), and evaluations of suicidality and sexual functioning. Patients will receive either paliperidone palmitate 50, 75, 100, or 150 mg eq. monthly by injection for two years or oral risperidone 2, 4, 6, or 8 mg tabs once daily for two years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
Drug: paliperidone palmitate
oral risperidone 2 4 6 or 8 mg tabs once daily for two years
Drug: oral risperidone
50, 75, 100, or 150 mg eq. monthly injection for 2 years
2, 4, 6, or 8 mg tabs once daily for two years
Time to Relapse During Relapse Prevention Phase
Time to relapse during the relapse prevention phase was the primary efficacy variable of the study. Each case of potential relapse event were to be reviewed in a blinded fasion by an independent Relapse Monitoring Board, comprised of experts in the diagnostic, clinical and therapeutic management of schizophrenia.
Time frame: 24 months
This trial was intended to recruit patients from multiple sites in North America, Europe, and Asia.
| Milestone | Paliperidone Palmitate |
|---|---|
| Started | 162 |
| Completed | 2 |
| Not completed | 160 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Study closed by sponsor | 139 |
| Withdrew: Failed to meet stability criteria | 2 |
| Withdrew: Prohibited medication during study | 1 |
| Withdrew: Patient moved away | 2 |
| Milestone | Paliperidone Palmitate |
|---|---|
| Started | 2 |
| Completed | 0 |
| Not completed | 2 |
| Withdrew: Study closed by sponsor | 2 |
Time to relapse during the relapse prevention phase was the primary efficacy variable of the study. Each case of potential relapse event were to be reviewed in a blinded fasion by an independent Relapse Monitoring Board, comprised of experts in the diagnostic, clinical and therapeutic management of schizophrenia.
No measurements were reported for this outcome.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Palmitate | — | 6/162 (3.7%) | 50/162 (30.9%) |
| Event | Paliperidone Palmitate |
|---|---|
| SchizophreniaPsychiatric disorders | 4/162 |
| AggressionPsychiatric disorders | 1/162 |
| DepressionPsychiatric disorders | 1/162 |
| Self Injurious BehaviourPsychiatric disorders | 1/162 |
| Hand FractureInjury, poisoning and procedural complications | 1/162 |
| Event | Paliperidone Palmitate |
|---|---|
| InsomniaPsychiatric disorders | 10/162 |
| Injection Site PainGeneral disorders | 10/162 |
| AgitationPsychiatric disorders | 8/162 |
| AnxietyPsychiatric disorders | 8/162 |
| HeadacheNervous system disorders | 8/162 |
| TremorNervous system disorders | 8/162 |
| Weight IncreasedInvestigations | 8/162 |
| AkathisiaNervous system disorders | 5/162 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 5/162 |
| RestlessnessPsychiatric disorders | 4/162 |
| Age Continuous(years) | Paliperidone Palmitate |
|---|---|
| Mean | 27 ± 4.55 |
| Age, Customized(participants) | Paliperidone Palmitate |
|---|---|
| 18-23 years | 46 |
| 24-29 years | 62 |
| 30-35 years | 54 |
| Sex: Female, Male(Participants) | Paliperidone Palmitate |
|---|---|
| Female | 54 |
| Male | 108 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale) | Paliperidone Palmitate |
|---|---|
| Mean | 85.9 ± 13.65 |
| Clinical Global Impression of Severity (CGI-S)(units on a scale) | Paliperidone Palmitate |
|---|---|
| Mean | 4.4 ± 0.56 |
| Age at First Diagnosis of Schizophrenia(years) | Paliperidone Palmitate |
|---|---|
| Mean | 24.1 ± 4.61 |
| Current Schizophrenia Diagnosis(participants) | Paliperidone Palmitate |
|---|---|
| Paranoid (295.30) | 142 |
| Disorganized (295.10) | 6 |
| Undifferentiated (295.90) | 13 |
| Residual (295.60) | 1 |
The record gives a start of Jun 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Ortho-McNeil Janssen Scientific Affairs, LLC →